Testing effectiveness (Phase 2)Active Not RecruitingNCT03474497
What this trial is testing
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
Who this might be right for
Non Small Cell Lung CancerMetastatic MelanomaMetastatic Renal Cell Carcinoma+1 more
Megan Daly, MD 18